Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | LATS1 | O95835 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 3/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 5/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | BUB1 | O43683 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 5/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 5/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.35 |
| ▸ | CSNK2B | P67870 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31356300 | 0.85 | LATS1 (0.53) | LATS1EGFRKDRCSNK2A1CSNK2A2 | |
| SCHEMBL27215791 | 0.83 | PIM1 (0.51) | EGFRCSNK2A1PIM1PIM2CSNK2A2 | |
| SCHEMBL31356301 | 0.83 | ABCG2 (0.48) | LATS1EGFRCSNK2A1PIM1PIM2 | |
| SCHEMBL31356290 | 0.83 | CSNK2A1 (0.52) | EGFRKDRCSNK2A1PIM1PIM2 | |
| SCHEMBL31485519 | 0.81 | IDO1 (0.45) | IDO1LATS1TDO2EGFRKDR | |
| SCHEMBL31356304 | 0.81 | ABCG2 (0.46) | CSNK2A1PIM1PIM2CSNK2A2CSNK2B | |
| SCHEMBL27165757 | 0.81 | CSNK2A1 (0.49) | CSNK2A1PIM1PIM2CSNK2A2CSNK2B | |
| SCHEMBL31356292 | 0.80 | PTK6 (0.53) | TDO2EGFRCSNK2A1 | |
| SCHEMBL31356294 | 0.79 | EPHB4 (0.47) | CSNK2A1PIM1PIM2CSNK2A2CSNK2B | |
| SCHEMBL31356295 | 0.79 | NFATC1 (0.40) | LATS1KDRCSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12168662-B1 | Pyrido[4′,3′:4,5]pyrrolo[2,3-c][2,7]naphthyridines compounds as CK2 inhibitors | King Faisal University (SA) | 2024-12-17 | — | — | US | claimed |
| US-12168662-B1 | Pyrido[4′,3′:4,5]pyrrolo[2,3-c][2,7]naphthyridines compounds as CK2 inhibitors | King Faisal University (SA) | 2024-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12168662-B1 | Pyrido[4′,3′:4,5]pyrrolo[2,3-c][2,7]naphthyridines compounds as CK2 inhibitors | CKS2, CDK2, PNKP | IDO1 818/4885LATS1 906/4885TDO2 774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.